

5/24/2020; Page 1

Suggeste	^d Ceftazidime 100 mg/mL Intravenous Injection (Solution, 10 mL)	FIN	F 008 724
Formu	a contactante roo mg me maavenous mjeetion (solution, ro me)		1 000 /21

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Ceftazidime with Sodium Carbonate	TBD					
Sterile Water for Injection, USP	8.0	mL				
Sterile Water for Injection, USP	q.s. to 10.0	mL				
Sodium Hydroxide 10% Solution	As required					
Hydrochloric Acid 10% Solution	As required					
			Q			

SPECIAL PREPARATORY CONSIDERATIONS


Ingredient-Specific Information

Light Sensitive (protect from light whenever possible):

Ceftazidime with Sodium Carbonate



5/24/2020; Page 2





5/24/2020; Page 3

Suggested Formula	Ceftazidime 100 mg/mL Intravenous Injection (Solution, 10 mL)	FIN	F 008 724	
----------------------	---	-----	-----------	--

SUGGESTED PREPARATION (for 10 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) :	Processing Error	Qty. to measure
Ceftazidime with Sodium Carbonate §	TBD				
Sterile Water for Injection, USP §	8.0	mL			
Sterile Water for Injection, USP §	q.s. to 10.0	mL			
Sodium Hydroxide 10% Solution §	As required		Š		
Hydrochloric Acid 10% Solution §	As required	C	XL		

* Takes into account increased batch size conversions and density conversions, if required.


§ Weigh / measure just prior to use.

Preparatory Instruction

IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique


1. Equipment sterilization:

Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.



5/24/2020; Page 4

Suggested Formula	Ceftazidime 100 mg/mL Intravenous Injection (Solution, 10 mL)	FIN	F 008 724				
2. <u>Ingr</u>	Ingredient quantification:						
A. I	Determine the potency of Ceftazidime with Sodium Carbonate based on the certificate of	analys	sis:				
			100%				
n	MINUS						
Ι	Loss on drying (from certificate of analysis)	_	%				
Ν	MINUS						
S	Sodium Carbonate concentration (from certificate of analysis)	-	%				
I	DIVIDED BY		100				
I	EQUALS						
	Quantity of dried and Sodium Carbonate free of Ceftazidime vith Sodium Carbonate, in decimal	-					
N	MULTIPLIED BY						
I	Assay on dried and Sodium Carbonate free basis result (from certificate of analysis)	-	%				
I	DIVIDED BY		100				
H	EQUALS						
i	. Potency of Ceftazidime with Sodium Carbonate (Ceftazidime equivalent), in decin	nal _					





5/24/2020; Page 6

Suggested Formula		Ceftazidime 100 mg/mL Intravenous Injection (Solution, 10 mL)	FIN	F 008 724		
5.	pH testing:					
	A. Draw an appropriate amount of the mixture (Step 4A).					
	B. Test the pH of the sample. It should lie between 5.0 and 7.5.					
	C. <u>I</u>	f the pH < 5.0 carefully add, in a dropwise fashion, the Sodium Hydroxide 10% Solution	to the	mixture:		
	2 3	 Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% Solution to the mixture. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% Solution. Re-test the pH. Continue to add the Sodium Hydroxide 10% Solution until the pH of 5.0 to 7.5 is obt IMPORTANT: Do not allow the pH to rise above 7.5. 				
	D. <u>I</u>	f the pH > 7.5, carefully add, in a dropwise fashion, the Hydrochloric Acid 10% Solution	to the	mixture:		
	2 3	 Draw and transfer 1 or 2 drops of the Hydrochloric Acid 10% Solution to the mixture. Stir for at least 5 minutes to evenly disperse the Hydrochloric Acid 10% Solution. Re-test the pH. Continue to add the Hydrochloric Acid 10% Solution until the pH of 5.0 to 7.5 is obtice. 				
		IMPORTANT: Do not allow the pH to fall below 5.0.				
6.	Filling to volume:					
	A. Add additional Sterile Water for Injection to the above mixture to fill to the required batch size (10.0 mL <i>plus</i> processing error adjustments).					
	Specifications: Continuously mix.					
	End result: Homogeneous liquid-like solution.					
7.	Filter	ing and transferring:				
	Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.					
8.	Filte	r integrity test:				
		ate filter integrity by performing a filter stress test. If the test demonstrates that the filter on must be discarded and remade.	might	be defective, the		



5/24/2020; Page 7

		ggested formula	ftazio	dime 100 mg/mL Intravenous Injection (Solution	on, 10	mL)	FIN	F 008 724
	9.	Terminal Sterilization:						
		In relation to the chemical composition of the formulation, final packaging, etc., select and validate an end-stage sterilization method and follow the manufacturer's specification.						
	10.	Sterility a	and]	Endotoxin testing:				
		Validate t	he T	est sample for sterility and endotoxins, in accor	dance	e to current USP 797 regula	atory g	uidelines.
SU	GGE	STED PRI	ESE	NTATION		œ		
	24 hours controlled room temperature, 3 days refrigerated or 45 days frozen				Sterile, light-resistant un	it-dose	injection vials.	
			1	Use as directed. Do not exceed prescribed dose.	7	Equilibrate to room temp	oeratur	e before use.
		Auxiliary Labels	2	Keep out of reach of children.	8	Preservative free solu Discard any unused por		single use only.
			3	Do not use if product changes color.	9	Consult your health of prescription or over-the currently being used or use.	-count	er medications are
			4	Discard in the presence of particulate matter.	10	Discard container after u	se.	
			5	Keep at controlled room temperature, $(20^{\circ}C - 25^{\circ}C)$, refrigerated $(2^{\circ}C - 8^{\circ}C)$ or frozen $(-25^{\circ}C \text{ to } -10^{\circ}C)$.	11	Hypertonic solution. In	nject sl	lowly.
			6	Protect from light.				
	F	Pharmacist Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.						

Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.

Patient Instructions Contact your pharmacist in the event of adverse reactions.



5/24/2020; Page 8

Suggested Formula	Ceftazidime 100 mg/mL Intravenous Injection (Solution, 10 mL)	FIN	F 008 724

REFERENCES

1.	Parenteral Preparations. In: Allen, LV, Jr. <i>The Art, Science, and Technology of Pharmaceutical Compounding Fifth Edition</i> . American Pharmacists Association; 2016: 399.
2.	Fortaz. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialties, 2017: 1430.
3.	Ceftazidime. In: Brayfield, A., ed. <i>Martindale: The Complete Drug Reference, 38th Edition</i> . London, England: The Pharmaceutical Press; 2014: 250.
4.	Ceftazidime (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #1948.
5.	Ceftazidime. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations</i> , 5 th Edition. American Pharmaceutical Association; 2012: 98.
6.	Cefoxitin Sodium (Monograph). United States Pharmacopeia XLIII / National Formulary 38. Rockville, MD. US Pharmacopeial Convention, Inc. 2020: 872.
7.	Chapter 8: Buffered and Isotonic Solutions. In: Sinko, D. J. and Singh, Y. <i>Martin's Physical Pharmacy and Pharmaceutical Sciences, Sixth Edition</i> . Philadelphia, PA: Lipponcott Williams & Wilkins; 2011: 163-181.
8.	Chapter 18: Tonicity, Osmoticity, Osmolality and Osmolarity. In: D.B Troy. <i>Remington: The Science and Practice of Pharmacy</i> , 21st Edition. Baltimore, MD: Lippincott Williams & Wilkins; 2006: 250~265.
9.	Ceftazidime. Thomson Micromedex. USP DI – Drug Information for the Health Care Professional, 26 th Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 841.
10	D. USP <797>. United States Pharmacopeia XLIII / National Formulary 38. Rockville, MD. US Pharmacopeial Convention, Inc. 2020: 7037.

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.